Literature DB >> 6294783

Levels of cefotaxime in body fluids and tissues: a review.

W J Novick.   

Abstract

Cefotaxime is a third-generation cephalosporin with a broad spectrum of activity. Concentrations of cefotaxime in serum and urine are sufficient for clinical efficacy. This report reviews the available data on the penetration of cefotaxime into other body fluids and tissues. Therapeutic doses of cefotaxime result in significant levels in bile (20 micrograms/ml), in cerebrospinal fluid of patients with meningitis (5-10 micrograms/ml), in pleural fluid (2-7 micrograms/ml), and in otitis media exudate (2-10 micrograms/ml). Lower levels of cefotaxime are obtained in uninflamed aqueous humor (1 microgram/ml), in breast milk (0.1-0.5 microgram/ml), and in cerebrospinal fluid of patients without meningitis (0.2 microgram/ml). Cefotaxime levels in tissues are generally well within the range required for clinical efficacy--i.e., 2-5 micrograms/g, with some higher levels reported in testis, prostate, ureter, skin, and gallbladder wall. Drug levels of less than 2 micrograms/g have been reported in fat, muscle, and uterus. All body fluids and tissues, including bone and skin, are penetrated easily by therapeutic doses of cefotaxime.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6294783     DOI: 10.1093/clinids/4.supplement_2.s346

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  5 in total

1.  Comparison of agar dilution, microdilution, and disk elution methods for measuring the synergy of cefotaxime and its metabolite against anaerobes.

Authors:  J A Smith; D Henry; J Ngui-Yen; A Castell; S Coderre
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

2.  The pharmacokinetics of new cephalosporins: significance in clinical practice.

Authors:  H C Neu
Journal:  Bull N Y Acad Med       Date:  1984-05

Review 3.  Selective decontamination of the digestive tract: the mechanism of action is control of gut overgrowth.

Authors:  Luciano Silvestri; Miguel A de la Cal; Hendrick K F van Saene
Journal:  Intensive Care Med       Date:  2012-09-22       Impact factor: 17.440

Review 4.  Management of infections due to antibiotic-resistant Streptococcus pneumoniae.

Authors:  S L Kaplan; E O Mason
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

5.  Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?

Authors:  Yarmarly C Guerra Valero; Tavey Dorofaeff; Mark G Coulthard; Louise Sparkes; Jeffrey Lipman; Steven C Wallis; Jason A Roberts; Suzanne L Parker
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.